BofA Raises Price Target on Pfizer Following Strong Q1 Results
💡 Bank of America raises Pfizer's price target after strong Q1 results, citing growing confidence in the company's pipeline.
The pharmaceutical giant reported a 94% increase in quarterly revenue, driven by the success of its COVID-19 vaccine and other products. 's strong Q1 results have caught the attention of Wall Street analysts, who are reassessing their forecasts for the company's growth prospects.
BofA Raises Price Target on Pfizer
Bank of America Merrill Lynch raised its price target on Pfizer to $54, up from $48, following the company's strong Q1 results. The investment bank cited growing confidence in Pfizer's pipeline, which includes several promising biologics and vaccines. Pfizer's COVID-19 vaccine remains a key driver of revenue growth, with the company expecting to generate $22 billion in sales from the shot in 2023.
Pfizer's Q1 Revenue Surges 94%
Pfizer's Q1 revenue surged 94% year-over-year to $25.7 billion, driven by the success of its COVID-19 vaccine and other products. The company's vaccine sales more than doubled to $13.2 billion, while its oncology and rare disease sales also rose significantly. Pfizer's strong Q1 results have exceeded analysts' expectations, with many now revising their forecasts for the company's full-year growth prospects.
What's Next for Pfizer's Stock?
💬 Pfizer's stock price has risen 15% in the past month, outpacing the broader market. The company's strong Q1 results have reinforced investors' confidence in its ability to deliver sustained growth. However, some analysts remain cautious, citing concerns about Pfizer's high valuation and the potential impact of regulatory headwinds on its pipeline. Do you think Pfizer's stock will hold above $50? Share your view in the comments.
0 Comments
Sign in or create a free account to join the conversation.
Loading comments…